Trial
NCT01599832
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
National Cancer Institute (NCI)
Condition
Clear Cell Renal Cell Carcinoma
Intervention
pazopanib hydrochloride
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-08